LIAO Caiyun, LI Yiyun, YAO Wenbing, WEN Baoshu. Dissemination Processes of the Chinese Orange Book: An Empirical Study[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 810-812.
[1] Liu YT.China’s drug innovation system has taken a solid step - the first catalogue of listed drugs in China was released[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2018(1): 5-7. [2] Center for Drug Evaluation, NMPA. Regarding the public solicitation of the procedures and requirements for the collection of“The Catalogue of Newly Approved and Listed Chemical Drugs and the Quality and Efficacy Consistency Evaluation of Generic Drugs” (Trial) (Draft for Solicitation of Comments) [EB/OL]. (2020-10-29)[2021-04-13]. http://www.cde.org.cn/news.do?method=viewInfoCommon&id=27a995c05fd2f285. [3] National Medical Products Administration. Announcement of the General Administration on Issuing the“List of Listed Drugs in China”[EB/OL]. (2017-12-29)[2021-04-13]. https://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20171229100201920.html. [4] Lasswell H.The Structure and Function of Communication in Society(社会传播的结构与功能)[M]. Beijing: Communication University of China Press, 2013. [5] Food and Drug Administration. Listing of patent information in the orange book; establishment of a public docket; request for comments[J]. U.S. Food & Drug Administration Documents/Find, 2020, 85(105): 33169-33173. [6] Food and Drug Administration. Orange book-questions and answers; draft guidance for industry; availability[J]. U.S. Food & Drug Administration Documents/FIND, 2020, 85(105): 33167-33169.